Limits...
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.

Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW - Br. J. Cancer (2002)

Bottom Line: Progression-free survival was also significantly longer for patients receiving marimastat compared to placebo (P=0.009, hazard ratio=1.32 (1.07-1.63)).Marimastat treatment was associated with the development of musculoskeletal pain and inflammation.This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK. S.R.Bramhall@bham.ac.uk

Show MeSH

Related in: MedlinePlus

Overall survival (Chemotherapy sub-group).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375430&req=5

fig2: Overall survival (Chemotherapy sub-group).

Mentions: Analysis of overall survival in the predefined sub-group of patients who had received prior chemotherapy revealed a significant benefit for marimastat at the primary analysis point (P=0.045 log-rank test, HR=1.53 (1.00–2.34)). This survival difference increased with 2 years of additional follow-up (P=0.006 log-rank test, HR=1.68 (1.16–2.44)), with median survival times of 253 days for marimastat and 175 days for placebo, and 2-year survival of 18% and 5% respectively (Figure 2Figure 2


Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.

Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW - Br. J. Cancer (2002)

Overall survival (Chemotherapy sub-group).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375430&req=5

fig2: Overall survival (Chemotherapy sub-group).
Mentions: Analysis of overall survival in the predefined sub-group of patients who had received prior chemotherapy revealed a significant benefit for marimastat at the primary analysis point (P=0.045 log-rank test, HR=1.53 (1.00–2.34)). This survival difference increased with 2 years of additional follow-up (P=0.006 log-rank test, HR=1.68 (1.16–2.44)), with median survival times of 253 days for marimastat and 175 days for placebo, and 2-year survival of 18% and 5% respectively (Figure 2Figure 2

Bottom Line: Progression-free survival was also significantly longer for patients receiving marimastat compared to placebo (P=0.009, hazard ratio=1.32 (1.07-1.63)).Marimastat treatment was associated with the development of musculoskeletal pain and inflammation.This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK. S.R.Bramhall@bham.ac.uk

Show MeSH
Related in: MedlinePlus